Interleukin-2: Evaluation of routes of administration and current delivery systems in cancer therapy

Journal of Pharmaceutical Sciences

Volumn 98, Issue 7, 2009, Pages 2268-2298

  Shaker, Mohamed A ^a   Younes, Husam M ^a,b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Qatar University ^*  (Qatar)

Author keywords

Cancer; Controlled release; Pharmacokinetics; Physicochemical properties; Polymeric drug delivery systems; Protein delivery

Indexed keywords

ADENOVIRUS VECTOR; ALBULEUKIN; ALPHA TOCOPHEROL; CHITOSAN; CHONDROITIN SULFATE; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; EUDRAGIT; FLUOROURACIL; FOLINIC ACID; GELATIN; IFOSFAMIDE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; INTERKING; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; LIPOSOME; MACROGOL; MICROSPHERE; NANOPARTICLE; PLASMID DNA; POLYCAPROLACTONE; POLYGLACTIN; POLYGLUTAMIC ACID; POLYMER; RECOMBINANT INTERLEUKIN 2; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ASCITES; BASAL CELL CARCINOMA; BILIRUBIN BLOOD LEVEL; BLADDER CARCINOMA; BLOOD PRESSURE; BODY WEIGHT; BREAST ADENOCARCINOMA; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CHILL; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; CONTROLLED RELEASE FORMULATION; CREATININE BLOOD LEVEL; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; EYE CANCER; FEVER; FLU LIKE SYNDROME; GENE; GENE THERAPY; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HEART ARRHYTHMIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEL; HYPERBILIRUBINEMIA; HYPOTENSION; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; INTERLEUKIN 2 GENE; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LOW DRUG DOSE; LUNG CANCER; LYMPHOMA; MAINTENANCE THERAPY; MALAISE; MEDIASTINUM METASTASIS; MELANOMA; MESOTHELIOMA; METASTASIS; MICROENCAPSULATION; MINIMAL RESIDUAL DISEASE; NANOENCAPSULATION; NASOPHARYNX CARCINOMA; NAUSEA; NEOPLASM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OLIGURIA; OVARY CARCINOMA; PHYSICAL CHEMISTRY; PLEURA EFFUSION; PROSTATE ADENOCARCINOMA; PROTEIN BLOOD LEVEL; RASH; REVIEW; SARCOMA; SIDE EFFECT; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 67650165335     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21596     Document Type: Review

References (194)

1. Morgan DA, Ruscetti FW, Gallo R. 1976. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007-1008.
2. Smith KA. 1988. Interleukin-2: Inception, impact, and implications. Science 240:1169-1176.
3. Smith KA. 1990. Cytokines in the nineties. Eur Cytokine Netw 1:7-13.
4. Bubenik J, Perlmann P, Indrova M, Simova J, Jandlova T, Neuwirt J. 1983. Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)- containing preparations. Preliminary report. Cancer Immunol Immunother 14:205-206.
5. Culliton BJ. 1992. FDA panel backs interleukin-2. Nature 355:287.
6. Bachmann MF, Wolint P, Walton S, Schwarz K, Oxenius A. 2007. Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections. Eur J Immunol 37:1502-1512. (Pubitemid 46947854)
7. Chiarion-Sileni V, Bianco PD, Romanini A, Guida M, Paccagnella A, Palma MD, Naglieri E, Ridolfi R, Silvestri B, Michiara M, Salvo GL. 2006. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: A randomized phase III Italian melanoma inter-group trial. BMC Cancer 6:44-53.
8. Rosenberg SA, Spiess P, Lafreniere R. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321. (Pubitemid 16002234)
9. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwartz M, Garbe C. 2003. Phase II trial of intralesional therapy with interleukin-2 in soft tissue melanoma metastases. Br J Cancer 89:1620-1626. (Pubitemid 37464130)
10. Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM. 1988. Repetitive weekly cycles of recombinant human interleukin. 2:Responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 80:60-63. (Pubitemid 18076571)
11. Gisselbrecht C, Maraninchi D, Pico JL, Milpied N, Coiffier B, Divine M, Tiberghien P, Body A, Tilly H, Boulat O, Brandely M. 1994. Interleukin-2 treatment in lymphoma: A phase II multicenter study. Blood 83:2081-2085. (Pubitemid 24112718)
12. Shirai M, Watanabe S, Nishioka M. 1990. Antitumour effect of intratumoral injection of human recombinant interleukin-2 in patients with hepatocellular carcinoma: A preliminary report. Eur J Cancer 26:1045-1048.
13. Cortesina G, De-Stefani A, Giovarelli M, Barioglio MG, Cavallo GP, Jemma C, Forni G. 1988. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 12:2482-2485. (Pubitemid 19006426)
14. Simpson WG, Heys SD, Whiting PH, Eremin O, Broom I. 1995. Acute phase proteins and recombinant interleukin-2 therapy: Prediction of response and survival in patients with colorectal cancer. Clin Exp Immunol 99:143-147.
15. Ferlazzo G, Magno C, Lupo G, Rizzo M, Iemmo R, Semino C, Melioli G. 1995. A phase I study of intravesical continuous perfusion of recombinant interleukin-2 in patients with super Wcial bladder cancer. Am J Clin Oncol 18:100-104.
16. Jacobs JJL, Hordijk GJ, Jü rgenliemk-Schulz IM, Terhaard CHJ, Koten JW, Battermann JJ, Den Otter W. 2005. Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2. Cancer Immunol Immunother 54:792-798.
17. Astoul P, Picat-Joossen D, Viallat JR, Boutin C. 1998. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: A Phase II study. Cancer 83:2099-2104. (Pubitemid 28525391)
18. Krastev Z, Koltchakov C, Tomova R, Deredjian S, Alexiev A, Popov D, Tomov B, Koten JW, Jacobs J, Den Otter W. 2005. Locoregional IL-2 low dose application for gastrointestinal tumors. World J Gastroenterol 11:5525-5529. (Pubitemid 41684713)
19. Taylor DD, Edwards RP, Case CR, Gercel-Taylor C. 2004. Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients. Gynecol Oncol 94:54-60. (Pubitemid 38950498)
20. Yasumoto K, Mivazaki K, Nagashima A, Ishida T, Kuda T, Yano T, Sugimachi K, Nomoto K. 1987. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin- 2 in patients with malignant pleurisy due to lung cancer. Cancer Res 8:2184-2187. (Pubitemid 17074630)
21. Masotti A, Fumagalli L, Morandini GC. 1997. Intrapleural administration of recombinant interleukin- 2 in non-small cell lung cancer with neoplastic pleural effusion. Monaldi Arch Chest Dis 52:225-228. (Pubitemid 27379873)
22. Kaplan B, Moy RL. 2000. Effect of perilesional injections of PEG-interleukin-2 on basal cell carcinoma. Dermatol Surg 26:1037-1040. (Pubitemid 30836938)
23. Bubenik J, Mikyskova R, Vonka V, Mendoza L, Simova J, Smahel M, Indrova M. 2003. Interleukin- 2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine 21:891-896. (Pubitemid 36126423)
24. Mikyskova R, Indrova M, Simova J, Jandlova T, Bieblova J, Jinoch P, Bubenik J, Vonka V. 2004. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16- associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Int J Oncol 24:161-167.
25. Bubenik J, Simova J, Bubenikova D, Zeuthen J, Indrova M. 1995. Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment. J Cancer Res Clin Oncol 121:39-43.
26. Indrova M, Bubenik J, Mikyskova R, Mendoza L, Simova J, Bieblova J, Jandlova T, Jinoch P, Smahel M, Vonka V, Pajtasz-Piasecka E. 2003. Chemoimmunotherapy in mice carrying HPV16- associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int J Oncol 22:691-695.
27. Brivio F, Fumagalli L, Chiarelli M, Denova M, Bertolini A, Cetta M, Nespoli A. 2007. Immunotherapy in radical surgery of colorectal carcinoma. Chir Ital 59:635-640.
28. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD. 2007. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 156:337-345. (Pubitemid 46095963)
29. Durier C, Capitant C, Lascaux AS, Goujard C, Oksenhendler E, Poizot-Martin I, Viard JP, Weiss L, Netzer E, Delfraissy JF, Aboulker JP, Levy Y. 2007. Long-term effects of intermittent interleukin- 2 therapy in chronic HIV-infected patients (ANRS048-07 Trials). AIDS 21:1887-1897. (Pubitemid 47329765)
30. Golden-Mason L, Castelblanco N, O'Farrelly C, Rosen HR. 2007. Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection. J Virol 81:9292-9298. (Pubitemid 47311471)
31. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin- 2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897.
32. Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA. 1986. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58:2764-2772. (Pubitemid 17232941)
33. Waldmann TA. 2006. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol 6:595-601. (Pubitemid 44134092)
34. Malek TR. 2007. The biology of interleukin-2. Annu Rev Immunol 26:453-479.
35. Smith KA. 1984. Interleukin 2. Annu Rev Immunol 2:319-333.
36. Bachmann MF, Oxenius A. 2007. Interleukin 2: From immunostimulation to immunoregulation and back again. EMBO Rep 8:1142-1148. (Pubitemid 350201732)
37. Zhu MH, Berry JA, Russell SM, Leonard WJ. 1998. Delineation of the regions of interleukin-2 (IL-2) receptor beta chain important for association of Jak1 and Jak3. Jak1-independent functional recruitment of Jak3 to Il-2Rbeta. J Biol Chem 273:10719-10725. (Pubitemid 28227687)
38. Takeshita T, Arita T, Higuchi M, Asao H, Endo K, Kuroda H, Tanaka N, Murata K, Ishii N, Sugamura K. 1997. STAM, signal transducing adaptor molecule, is associated with Janus kinases and involved in signaling for cell growth and c-myc induction. Immunity 6:449-457. (Pubitemid 27208200)
39. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan KC, Yin L, Pennica D, Johnson EMJr, Schreiber RD. 1998. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine- induced biologic responses. Cell 93:373-383. (Pubitemid 28232082)
40. Ward SG, Cantrell DA. 2001. Phosphoinositide 3- kinases in T lymphocyte activation. Curr Opin Immunol 13:332-338.
41. Janssen RA, Mulder NH, The TH, de Leij L. 1994. The immunological effects of interleukin-2 in vivo. Cancer Immunol Immunother 39:207-216.
42. Bazan JZ, Mckay DB. 1992. Unraveling the structure of IL-2. Science 257:410-413.
43. Sasaoki K, Hiroshima T, Kusumoto S, Nishi K. 1992. Deamidation at asparagine-88 in recombinant human interleukin 2. Chem Pharm Bull (Tokyo) 40:976-980.
44. Wang W, Antonsen K, Wang YJ, Wang DQ. 2008. pH dependent effect of glycosylation on protein stability. Eur J Pharm Sci 33:120-127.
45. Pao-Li W, Thomas PJ. 1993. Thermal-induced denaturation of two model proteins: Effect of poloxamer 407 on solution stability. Int J Pharm 96:41-49. (Pubitemid 23233268)
46. Gounili P. 1999. PhD Thesis: The effect of pH and temperature on the conformational stability of recombinant human interleukin-2. University of Connecticut, USA.
47. Korner IJ, Dettmer R, Kopp J, Gaestel M, Malz W. 1986. Simple preparative two-step purification of interleukin-2 from culture medium of lectin-stimulated normal human lumphocytes. J Immunol Methods 87:185-191. (Pubitemid 16129042)
48. WelteK,WangCY,MertelsmannR,VenutaS,Feldman SP, Moore MA. 1982. Purification of human interleukin 2 to apparent homogeneity and itsmolecular heterogeneity. J ExpMed 156:454-464. (Pubitemid 12041407)
49. Wang A, Lu SD, Mark DF. 1984. Site-specific mutagenesis of the human interleukin-2 gene: Structure-function analysis of the cysteine residues. Science 224:1431-1433. (Pubitemid 14123340)
50. Maria CD, Brigitte TH. 2003. Native and recombinant interleukin-2, two functionally distinct molecules. Mol Immunol 40:279-286. (Pubitemid 37025743)
51. Cumming DA. 1991. Glycosylation of recombinant protein therapeutics: Control and functional implications. Glycobiology 1:115-130.
52. Robb RJ, Kutny RM, Panico M, Morris HR, Chowdhry V. 1984. Amino acid sequence and posttranslational modification of human interleukin 2. Proc Natl Acad Sci USA 81:6486-6490. (Pubitemid 15221859)
53. Liang SM, Thatcher DR, Liang CM, Allet B. 1986. Studies of structure-activity relationships of human interleukin-2. J Biol Chem 261:334-337. (Pubitemid 16103949)
54. Kashima N, Nishi-Takaoka C, Fujita T, Taki S, Yamada G, Hamuro J, Taniguchi T. 1985. Unique structure of murine interleukin-2 as deduced from cloned cDNAs. Nature 313:402-404. (Pubitemid 15198726)
55. Arkin MR, Randal M, Delano WL, Hyde J, Luong TN, Oslob JD, Raphael DR, Taylor L, Wang J, McDowell RS, Wells JA, Braisted AC. 2003. Binding of small molecules to an adaptive protein-protein interface. Proc Natl Acad Sci USA 100: 1603-1608. (Pubitemid 36254494)
56. Brandhuber BJ, Boone T, Kenney WC, McKay DB. 1987. Three-dimensional structure of interleukin- 2. Science 238:1707-1709.
57. Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA. 1985. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 134:157-166.
58. Goey SH, Eggermont AM, Punt CJ, Slingerland R, Gratama JW, Oosterom R, Oskam R, Bolhuis RL, Stoter G. 1995. Intrapleural administration of interleukin 2 in pleural mesothelioma: A phase I-II study. Br J Cancer 72:1283-1288.
59. Fathallah-Shaykh HM, Zimmerman C, Morgan H, Rushing E, Schold SC Jr, Unwin DH. 1996. Response of primary leptomeningeal melanoma to intrathecal recombinant interleukin-2. A case report. Cancer 77:1544-1550. (Pubitemid 26105392)
60. Meyers CA, Yung WK. 1993. Delayed neurotoxicity of intraventricular interleukin-2: A case report. J Neurooncol 15:265-267. (Pubitemid 23182719)
61. Den Otter W, Hill FW, Klein WR, Koten JW, Steerenberg PA, De Mulder PH, Rhode C, Stewart R, Faber JA, Ruitenberg EJ. 1995. Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol Immunother 41:10-14.
62. Thatcher N, Dazzi H, Johnson RJ, Russell S, Ghosh AK, Moore M, Chadwick G, Craig RD. 1989. Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A. phase I and II study. Br J Cancer 60:770-774. (Pubitemid 19275748)
63. Suda T, Hashizume H, Aoshima Y, Yokomura K, Sato J, Inui N, Nakamura Y, Fujisawa T, Enomoto N, Chida K. 2007. Management of interleukin-2 induced severe bronchoconstraction. Eur Reapir J 29:612-613. (Pubitemid 46372113)
64. Rhines LD, Sampath P, Di-Meco F, Lawson HC, Tyler BM, Hanes J, Olivi A, Brem H. 2003. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: A novel treatment for experimental malignant glioma. Neurosurgery 52:872-879. (Pubitemid 36402876)
65. Huland E, Heinzer H, Mir TS, Huland H. 1997. Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: Six years of experience. Cancer J Sci Am 3:S98-S105. (Pubitemid 127698069)
66. Konrad MW, Hemstreet G, Hersh EM, Mansell PW, Mertelsmann R, Kolitz JE, Bradley EC. 1990. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res 50:2009-2017.
67. Dillman RO. 1994. The clinical experience with interleukin-2 in cancer therapy. Cancer Biother 9:183-209. (Pubitemid 24314506)
68. Mekhail T, Wood L, Bukowski R. 2000. Interleukin- 2 in cancer therapy: Uses and optimum management of adverse effects. BioDrugs 14:299-318.
69. Melder RJ, Osborn BL, Riccobene T, Kanakaraj P, Wei P, Chen G, Stolow D, Halpern WG, Migone TS, Wang Q, Grzegorzewski KJ, Gallant G. 2005. Pharmacokinetics and in vitro and in vivo antitumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunol Immunother 54:535-547. (Pubitemid 40613036)
70. Thompson JA, Lee DJ, Cox WW, Lindgren CG, Collins C, Neraas KA, Dennin RA, Fefer A. 1987. Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res 47:4202-4207. (Pubitemid 17116354)
71. Kirchner GI, Franzke A, Buer J, Beil W, Probst-Kepper M, Wittke F, Overmann K, Lassmann S, Hoffmann R, Kirchner H, Ganser A, Atzpodien J. 1998. Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application. Br J Clin Pharmacol 46:5-10. (Pubitemid 28308418)
72. Gooding R, Riches P, Dadian G, Moore J, Gore M. 1995. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br J Cancer 72:452-455.
73. Rubin LA, Nelson DL. 1990. The soluble interleukin- 2 receptor: Biology, function, and clinical application. Ann Intern Med 113:619-627. (Pubitemid 20346191)
74. Lissoni P, Barni S, Tisi E, Rovelli F, Pittalis S, Rescaldani R, Vigore L, Biondi A, Ardizzoia A, Tancini G. 1993. In vivo biological results of the association between interleukin-2 and interleukin- 3 in the immunotherapy of cancer. Eur J Cancer 29A:1127-1132.
75. Voss SD, Hank JA, Nobis CA, Fisch P, Sosman JA, Sondel PM. 1989. Serum levels of low affinity interleukin-2 receptor molecule (TAC) during IL- 2 therapy reflect systemic lymphoid mass activation. Cancer Immunol Immunother 29:261-269. (Pubitemid 19166458)
76. Rubin LA, Kurmann CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL. 1985. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135: 3172-3177. (Pubitemid 16250575)
77. Lassalle P, Sergant M, Delneste Y, Gosset P, Wallaert B, Zandecki M. 1992. Levels of soluble IL-2 receptor in plasma from asthmatics. Correlations with blood eosinophilia, lung function, and corticosteroid therapy. Clin Exp Immunol 87:266-271.
78. Hänninen EL, Körfer A, Hadam M, Schneekloth C, Dallmann I, Menzel T, Kirchner H, Poliwoda H, Atzpodien J. 1991. Biological monitoring of lowdose interleukin-2 in humans: Soluble interleukin. 2 receptors, cytokines, and cell surface phenotypes. Cancer Res 50:6312-6316.
79. Waldmann T. 1993. The IL-2/IL-2-receptor system: A target for rational immune intervention. Immunol Today 14:264-270. (Pubitemid 23186988)
80. Noguchi M, Yoshiaki N, Russel SM, Ziegler SF, Tsang M, Cao X, Leonard WJ. 1993. Interleukin-2 receptor gamma-chain: A functional component of the interleukin-7 receptor. Science 262:1877-1880. (Pubitemid 24041859)
81. Pfohler C, Steinhauser S, Wagner A, Ugurel S, Tilgen W. 2004. Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma. Hautarzt 55:171-175.
82. Bubenik J, Indrova M. 1987. Cancer immunotherapy using local interleukin 2 administration. Immunol Lett 16:305-309. (Pubitemid 18011310)
83. Ewend MG, Thompson RC, Anderson R, Sills AK, Staveley-O'Carroll K, Tyler BM, Hanes J, Brat D, Thomas M, Jaffee EM, Pardoll DM, Brem H. 2000. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system. J Immunother 23:438-448. (Pubitemid 30457701)
84. Bubenik J. 1990. Local and regional immunotherapy of cancer with interleukin 2. J Cancer Res Clin Oncol 116:1-7. (Pubitemid 20132845)
85. Bubenik J. 2004. Interleukin-2 therapy of cancer. Folia Biol (Praha) 50:120-130.
86. Donohue JH, Rosenberg SA. 1983. The fate of interleukin-2 after in vivo administration. J Immunol 130:2203-2208.
87. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. 1995. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688-696.
88. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT. 1985. Observations on the systemic administration of autologous lymphokine- activated killer cells and recombinant interleukin- 2 to patients with metastatic cancer. N Engl J Med 313:1485-1492. (Pubitemid 16212345)
89. PizzaG, SeveriniG,Menniti D, De Vinci C,Corrado F. 1984. Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report. Int J Cancer 34:359-367. (Pubitemid 14032186)
90. Carpagnano GE, Spanevello A, Curci C, Salerno F, Palladino GP, Resta O, Di Gioia G, Carpagnano F, Foschino Barbaro MP. 2007. IL-2, TNF-alpha, leptin: Local versus systemic concentrations in NSCLC patients. Oncol Res 16:375-381. (Pubitemid 47413253)
91. Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Ettinghausen SE, White DE, Steinberg SM, Cole DJ, Kim HI. 1994. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report. J Clin Oncol 12:1572-1576. (Pubitemid 24244991)
92. Jacobs JJ, Sparendam D, Den Otter W. 2005. Local interleukin 2 therapy is most effective against cancer when injected intratumourally. Cancer Immunol Immunother 54:647-654. (Pubitemid 40884160)
93. Baselmans AH, Koten JW, Battermann JJ, Van Dijk JE, Den Otter W. 2002. The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol Immunother 51:492-498.
94. Caporale A, Brescia A, Galati G, Castelli M, Saputo S, Terrenato I, Cucina A, Liverani A, Gasparrini M, Ciardi A, Scarpini M, Cosenza UM. 2007. Locoregional IL-2 therapy in the treatment of colon cancer. Cell-induced lesions of a murine model. Anticancer Res 27:985-989.
95. Kudo-Saito C, Garnett CT, Wansley EK, Schlom J, Hodge JW. 2007. Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity. Cancer Immunol Immunother 56:1897-1910. (Pubitemid 47512611)
96. Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J. 1995. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76:840-852.
97. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van Der Meijden AP, Koten JW, Boon TA, Siedlar M, Zembala M. 1998. Intravesical interleukin-2 in T1 papillary bladder carcinoma: Regression of marker lesion in 8 of 10 patients. J Urol 159:1183-1186. (Pubitemid 28172790)
98. Dubinett SM, Patrone L, Tobias J, Cochran AJ, Wen DR, McBride WH. 1993. Intratumoral interleukin- 2 immunotherapy: Activation of tumorinfiltrating and splenic lymphocytes in vivo. Cancer Immunol Immunother 36:156-162. (Pubitemid 23047713)
99. Vaage J. 1991. Peri-tumor interleukin-2 causes systemic therapeutic effect via interferon-gamma induction. Int J Cancer 49:598-600.
100. Sone S, Ogura T. 1994. Local interleukin-2 therapy for cancer, and its effector induction mechanisms. Oncology 51:170-176. (Pubitemid 24056518)
101. Chi KH, Myers JN, Chow KC, Chan WK, Tsang YW, Chao Y, Yen SH, Lotze MT. 2001. Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology 60:110-115. (Pubitemid 32248707)
102. Den Otter W, Jacobs JJ, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, Stewart RJ, Ziekman PG, Koten JW. Local therapy of cancer with free IL-2. Cancer Immunol Immunother 57:931-950.
103. Bubenik J, Indrova M, Perlmann P, Berzins K, Mach O, Kraml J, Toulcova A. 1985. Tumour inhibitory effects of TCGF/IL-2/-containing preparations. Cancer Immunol Immunother 19:57-61. (Pubitemid 15110997)
104. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. 1987. Constant- infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898-905. (Pubitemid 17041980)
105. Bos GW, Jacobs JJ, Koten JW, Van Tomme S, Veldhuis T, van Nostrum CF, Den Otter W, Hennink WE. 2004. In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 therapy. Eur J Pharm Sci 21:561-567.
106. Naito K, Pellis NR, Kahan BD. 1988. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide. Cancer Res 48:101-108. (Pubitemid 18030337)
107. Da Pozzo LF, Hough KL, Holder WD Jr. 1992. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs. Surgery 111:326-334.
108. Nishimura T, Uchiyama Y, Yagi H, Hashimoto Y. 1986. Administration of slowly released recombinant interleukin 2. Augmentation of the efficacy of adoptive immunotherapy with lymphokineactivated killer (LAK) cells. J Immunol Methods 91:21-27. (Pubitemid 16037262)
109. Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Uchida N, Maekawa R, Hirano K. 2002. A significant enhancement of therapeutic effect against hepatic metastases of M5076 in mice by a liposomal interleukin-2 (mixture). J Control Release 82:183-187. (Pubitemid 34880177)
110. Aqeilan R, Kedar R, Ben-Yehudah A, Lorberboum-Galski H. 2003. Mechanism of action of interleukin- 2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor. Biochem J 370:129-140. (Pubitemid 36262022)
111. Lee HJ. 2002. Protein drug oral delivery: The recent progress. Arch Pharm Res 25:572-584. (Pubitemid 43104176)
112. Koren S, Fleischmann WR Jr. 1994. Modulation of peripheral leukocyte counts and bone marrow function in mice by oral administration of interleukin- 2. J Interferon Res 14:343-347.
113. Toth T, Cummins J, Moore D. 1994. Effects of very-low-dose oral cytokine treatment on hemato logical values in feline leukemia-positive cells. J Interferon Res 14:S187.
114. Georgiades JA, Fleischmann WR Jr. 1996. Oral application of cytokines. Biotherapy 8:205-212.
115. Semalty A, Semalty M, Singh R, Saraf SK, Saraf S. 2007. Properties and formulation of oral drug delivery systems of protein and peptides. Indian J Pharm Sci 69:741-747.
116. Hollinger MA. 1985. Respiratory pharmacology and toxicology (Saunders monographs in pharmacology and therapeutics). San Diego, California: WB Saunders. 1-20.
117. Enk AH, Nashan D, Rubben A, Knop J. 2000. High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma. Cancer 88:2042-2046. (Pubitemid 30233205)
118. Merimsky O, Gez E, Weitzen R, Nehushtan H, Rubinov R, Hayat H, Peretz T, Ben-Shahar M, Biran H, Katsenelson R, Mermershtein V, Loven D, Karminsky N, Neumann A, Matcejevsky D, Inbar M. 2004. Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin- 2. Ann Oncol 15:610-612. (Pubitemid 38559597)
119. Esteban-Gonzalez E, Carballido J, Navas V, Torregrosa Z, Munoz A, Mon MA. 2007. Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2. Anticancer Drugs 18:291-296. (Pubitemid 46192982)
120. Skubitz KM, Anderson PM. 2000. Inhalational interleukin-2 liposomes for pulmonary metastases: A phase I clinical trial. Anticancer Drugs 11:555-563. (Pubitemid 30740433)
121. Abdel-Wahab Z, Li WP, Osanto S, Darrow TL, Hessling J, Vervaert CE, Burrascano M, Barber J, Seigler HF. 1994. Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: A nude mouse model. Cell Immunol 159:26-39. (Pubitemid 24355065)
122. Hoffman DM, Figlin RA. 2000. Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol 18:152-156.
123. Johnston D, Reynolds SR, Bystryn JC. 2006. Interleukin- 2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice. Cancer Immunol Immunother 55:412-419. (Pubitemid 43076893)
124. Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Hirano K. 2003. Continuous release of interleukin-2 from liposomal IL-2 (mixture of interleukin-2 and liposomes) after subcutaneous administration to mice. Drug Dev Ind Pharm 29:1149-1153. (Pubitemid 37499550)
125. Hsu W, Lesniak MS, Tyler B, Brem H. 2005. Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma. J Neurooncol 74:135-140. (Pubitemid 41478908)
126. Samlowski WE, McGregor JR, Jurek M, Baudys M, Zentner GM, Fowers KD. 2006. ReGel polymerbased delivery of interleukin-2 as a cancer treatment. J Immunother 29:524-535. (Pubitemid 44395277)
127. Hiemstra C, Zhong Z, Van Tomme Sr, van Steenbergen MJ, Jacobs JJ, Den Otter W, Hennink WE, Feijen J. 2007. In vitro and in vivo protein delivery from in situ forming poly(ethylene glycol)-poly(lactide) hydrogels. J Control Release 119:320-327.
128. Gu F, Neufeld R, Amsden B. 2007. Sustained release of bioactive therapeutic proteins from a biodegradable elastomeric device. J Control Release 117:80-89. (Pubitemid 46161863)
129. Knauf MJ, Bell DP, Hirtzer P, Luo ZP, Young JD, Katre NV. 1988. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem 263:15064-15070. (Pubitemid 18251938)
130. Harris JM, Martin NE, Modi M. 2001. Pegylation: A novel process for modifying pharmacokinetics. Clin Pharmacokinet 40:539-551. (Pubitemid 32738660)
131. Fontana A, Spolaore B, Mero A, Veronese FM. 2008. Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv Drug Deliv Rev 60:13-28. (Pubitemid 350181164)
132. Turturro F. 2007. Denileukin diftitox: A biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther 7:11-17. (Pubitemid 46157644)
133. Yao Z, Dai W, Perry J, Brechbiel MW, Sung C. 2004. Effect of albumin fusion on the biodistribution of interleukin-2. Cancer Immunol Immunother 53:404-410. (Pubitemid 38657253)
134. Sobol RE, Royston I, Fakhrai H, Shawler DL, Carson C, Dorigo O, Gjerset R, Gold DP, Koziol J, Mercola D. 1995. Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): A phase I study. Hum Gene Ther 6:195-204.
135. Cao X, Chen C, Zhang W, Tao Q, Yu Y, Ye T. 1996. Enhanced efficacy of combination of IL-2 gene and IL-6 gene-transfected tumor cells in the treatment of established metastatic tumors. Gene Ther 3:421-426. (Pubitemid 26171340)
136. Vieweg J, Boczkowski D, Roberson KM, Edwards DW, Philip M, Philip R, Rudoll T, Smith C, Robertson C, Gilboa E. 1995. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 55:2366-2372.
137. Toloza EM, Hunt K, Swisher S, McBride W, Lau R, Pang S, Rhoades K, Drake T, Belldegrun A, Glaspy J, Economou JS. 1996. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther 3:11-17.
138. Parker SE, Khatibi S, Margalith M, Anderson D, Yankauckas M, Gromkowski SH, Latimer T, Lew D, Marquet M, Manthorpe M, Hobart P, Hersh E, Stopeck AT, Norman J. 1996. Plasmid DNA gene therapy: Studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther 3:175-185. (Pubitemid 126732439)
139. Saffran DC, Horton HM, Yankauckas MA, Anderson D, Barnhart KM, Abai AM, Hobart P, Manthorpe M, Norman JA, Parker SE. 1998. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: Induction of CD8+ T-cell immunity. Cancer Gene Ther 5:321-330. (Pubitemid 128640019)
140. Kupfer J. 1997. DNA delivery vectors for somatic cell gene therapy. In: Park E, editor. Controlled drug delivery: Challenges and stategies. Washington DC: American Chemical Society. pp 27-48.
141. Griscelli F, Opolon P, Saulnier P, Mami-Chouaib F, Gautier E, Echchakir H, Angevin E, Le Chevalier T, Bataille V, Squiban P, Tursz T, Escudier B. 2003. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Ther 10:386-395. (Pubitemid 36372446)
142. Lehrman S. 1999. Virus treatment questioned after gene therapy death. Nature 401:517-518.
143. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A. 2003. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348:255-256. (Pubitemid 36077924)
144. Zhao Z, Leong KW. 1996. Controlled delivery of antigens and adjuvants in vaccine development. J Pharm Sci 85:1261-1270. (Pubitemid 27014177)
145. Bergers JJ, Den Otter W, Dullens HFJ, Kerkvliet CTM, Crommelin DJA. 1993. Interleukin-2-containing liposomes: Interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines. Pharm Res 10:1715-1721. (Pubitemid 24000354)
146. Kulkarni SS, Kasi LP, Tucker SL, Pizzini RP. 1987. In vivo augmentation of mitogen response by liposome-encapsulated interleukin-2 in mice. Ann NY Acad Sci 507:344-347.
147. Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Hirano K. 2001. A novel and simple type of liposome carrier for recombinant interleukin-2. J Pharm Pharmacol 53:295-302. (Pubitemid 32229188)
148. Koppenhagen FJ, Visser AJW, Herron JN, Storm G, Crommelin DJA. 1998. Interaction of recombinant interleukin-2 with liposomal bilayers. J Pharm Sci 87:707-714. (Pubitemid 28268569)
149. Neville ME, Boni LT, Pflug LE, Popescu MC, Robb RJ. 2000. Biopharmaceutics of liposomal interleukin 2, oncolipin. Cytokine 12:1691-1701.
150. van Slooten ML, Storm G, Zoephel A, kupcu Z, Boerman O, Crommelin DJA, Wagner E, Kircheis R. 2000. Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines. Pharm Res 17:42-48.
151. De Groot CJ, Cadee JA, Koten JW, Hennink WE, Den Otter W. 2002. Therapeutic efficacy of IL-2-loaded hydrogels in a mouse tumor model. Int J Cancer 98:134-140. (Pubitemid 34113430)
152. Cadee JA, De Groot CJ, Jiskoot W, Den Otter W, Hennink WE. 2002. Release of recombinant human interleukin-2 from dextran-based hydrogels. J Control Release 78:1-13. (Pubitemid 34081848)
153. Fujiwara T, Sakagami K, Matsuoka J, Shiozaki S, Fujioka K, Takada Y, Uchida S, Onoda T, Orita K. 1991. Augmentation of antitumor effect on syngeneic murine solid tumors by an interleukin 2 slow delivery system, the IL-2 mini-pellet. Biotherapy 3:203-209.
154. Qiao M, Chen D, Hao T, Zhao X, Hu H, Ma X. 2008. Injectable thermosensitive PLGA-PEG-PLGA triblock copolymers-based hydrogels as carriers for interleukin-2. Pharmazie 63:27-30. (Pubitemid 351155200)
155. Lynn AK, Yannas IV, Bonfield W. 2004. Antigenicity and immunogenicity of collagen. J Biomed Mater Res B Appl Biomater 71:343-354.
156. Kumagai T, Kamada M, Igarashi C, Yuri K, Furukawa H, Nagata N, Saito A, Okui T, Yano S. 2002. Gelatin-specific cellular immune responses persist for more than 3 years after priming with gelatin containing DTaP vaccine. Clin Exp Allergy 32:1510-1514. (Pubitemid 35278921)
157. Hora MS, Rana RK, Nunberg JH, Tice TR, Gilley RM, Hudson ME. 1990. Controlled release of interleukin-2 from biodegradable microspheres. Biotechnology (NY) 8:755-758. (Pubitemid 20331294)
158. Thomas TT, Kohane DS, Wang A, Langer R. 2004. Mircoparticlulate formulations for the controlled release ofinterleukin-2. J Pharm Sci 93:1100-1109.
159. Sharma A, Harper CM, Hammer L, Nair RE, Mathiowitz E, Egilmez NK.2004. Characterization of cytokine encapsulated controlled-release microsphere adjuvants. Cancer Biother Radiol 19:764-769.
160. Egilmez NK, Jong YS, Iwanuma Y, Jacob JS, Santos CA, Chen FA, Mathiowitz E, Bankert RB. 1998. Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model. Cancer Immunol Immunother 46:21-24. (Pubitemid 28133401)
161. Ozbas-Turan S, Akbuga J, Aral C. 2002. Controlled release of interleukin-2 from chitosan microspheres. J Pharm Sci 91:1245-1251.
162. Liu LS, Lius SQ, Ng SY, Froix M, Ohno T, Heller J. 1997. Controlled release of interleukin- 2 for tumour immunotherapy using alginate/ chitosan porous microspheres. J Control Release 43:65-74. (Pubitemid 26393609)
163. Cadee JA, Brouwer LA, Den Otter W, Hennink WE, Van Luyn MJA. 2001. A comparative biocompatibility study of microspheres based on crosslinked dextran or poly (lactic-co-glycolic) acid after subcutaneous injection in rats. J Biomed Mater Res 56:600-609. (Pubitemid 32606020)
164. Koten JW, Van Luyn MJA, Cadee JA, Brouwer L, Hennink WE, Bijleveld C, Den Otter W. 2003. IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy. Cytokine 24:57-66. (Pubitemid 37324032)
165. Hanes J, Sills A, Zhao Z, Suh KW, Tyler B, DiMeco F, Brat DJ, Choti MA, Leong KW, Pardoll DM, Brem H. 2001. Controlled local delivery of interleukin- 2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 18:899-906. (Pubitemid 32799932)
166. Spenlehauer G, Vert M, Benoit JP, Chabot F, Veillard M. 1988. Biodegradable cisplastin microspheres prepared by the solvent evaporation method: Morphology and release characteristics. J Control Release 7:217-229. (Pubitemid 18224728)
167. Mehta RC, Thanoo BC, Deluca PP. 1996. Peptide containing microspheres from low molecular weight and hydrophilic poly (d,l-lactide-co-glycolide). J Control Release 41:249-257.
168. Lee VHL, editor. 1991. Changing needs in drug delivery in the era of peptide and protein drugs. In: Peptide and protein drug delivery. New York: Marcel Dekker. pp 1-56.
169. Cohen FE, Kosen PA, Kuntz ID, Epstein LB, Ciardelli TL, Smith KA. 1986. Structure-activity studies of interleukin-2. Science 234:349-352.
170. Oeswein JQ, Shire SJ. 1991. Physical biochemistry of protein drugs. In: Lee VHL, editor. Peptide and protein drug delivery. New York: Marcel Dekker. pp 167-202.
171. Fu K, Pack DW, Laverdiere A, Son S, Langer R. 1998. Vizualization of pH in degrading polymer microspheres. Proc Int Symp Control Release Bioact Mater 25:150-151.
172. Hora MS, Rana RK, Nunberg JH, Tice TR, Gilley RM. 1990. Release of human serum albumin from poly (lactide-co-glycolide) microspheres. Pharm Res 7:1190-1194.
173. Atkins TW, Peacock SJ. 1996. The incorporation and release of bovine serum albumin from poly(beta-hydroxybutyrate-hydroxyvalerate) microspheres. J Biomater Sci Polym Ed 7:1065-1073. (Pubitemid 26300588)
174. Michaels AS, Guilod MS. 1979. Osmotic bursting drug delivery device. US patent no. 4177256.
175. Younes HM. 2002. PhD Thesis: New biodegradable elastomers for interferon-g delivery. University of Alberta, Canada.
176. Shaker MA, Younes HM. 2008. Synthesis and characterization of poly (diol-tricarballylate) photocrosslinked biodegradable elastomers. Am J Pharm Ed 72:118.
177. Tsung M, Burgess DJ. 1997. Preparation and characterization of heparin/gelatin microspheres. J Pharm Sci 5:603-607.
178. Bigi A, Cojazzi G, Panzavolta S, Rubini K, Roveri N. 2001 Mechanical and thermal properties of gelatin films at different degrees of glutaraldehyde crosslinking. Biomaterials 22:763-768. (Pubitemid 32146149)
179. Speer DP, Chvapil M, Eskelson CD, Ulreich J. 1980. Biological effects of residual glutaraldehyde in glutaraldehyde-tanned collagen biomaterials. J Biomed Mater Res 14:753-764. (Pubitemid 11234031)
180. Coombes GA, Lin W, O'Hagen DT, Davis SS. 1999. Preparation of protein microspheres, films and coatings. US Patent no. 6007791.
181. Paul W, Sharma CP. 2000. Chitosan: A drug carrier for the 21st century: A review. STP Pharm Sci 10:5-22. (Pubitemid 30126781)
182. Eiselt P, Yeh J, Latvala RK, Shea LD, Mooney DJ. 2000. Porous carriers for biomedical applications based on alginate hydrogels. Biomaterials 21:1921-1927. (Pubitemid 30433820)
183. Li L, Schwendeman SP. 2005. Mapping neutral microclimate pH in PLGA microspheres. J Control Release 101:163-173. (Pubitemid 39600980)
184. Chan YP, Meyrueix R, Kravtzoff R, Nicolas F, Lundstrom K. 2007. Review on Medusa: A polymer- based sustained release technology for protein and peptide drugs. Expert Opin Drug Deliv 4:441-451. (Pubitemid 47249141)
185. GuF,YounesHM,El-KadiAO,NeufeldRJ,Amsden BG. 2005. Sustained interferon-gamma delivery from a photocrosslinked biodegradable elastomer. J Control Release 102:607-617. (Pubitemid 40170204)
186. Glenn FV, Rex MT. 1995. UVA radiation-induced oxidative damage to lipids and proteins in vitro and in human skin fibroblasts is dependent on iron and singlet oxygen. Free Radic Biol Med 18:721-730.
187. Stewart RJ, Hill FW, Masztalerz A, Jacobs JJ, Koten JW, Den Otter W. 2006. Treatment of ocular squamous cell carcinomas in cattle with interleukin- 2. Vet Rec 159:668-672. (Pubitemid 44823366)
188. Castagneto B, Zai S, Mutti L, Lazzaro A, Ridolfi R, Piccolini E, Ardizzoni A, Fumagalli L, Valsuani G, Botta M. 2001. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. Lung Cancer 31:303-310. (Pubitemid 32107025)
189. Moiseeva EV, Merkulova IB, Bijleveld C, Koten JW, Miroshnikov AI, Den Otter W. 2003. Therapeutic effect of a single peritumoural dose of IL-2 on transplanted murine breast cancer. Cancer Immunol Immunother 52:487-496. (Pubitemid 36963210)
190. Lafreniere R, Rosenberg SA. 1985. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 45:3735-3741. (Pubitemid 15226452)
191. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL. 1985. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161:1169-1188. (Pubitemid 15011332)
192. Kusnierczyk H, Pajtasz-Piasecka E, Koten JW, Bijleveld C, Krawczyk K, Den Otter W. 2004. Further development of local IL-2 therapy of cancer: Multiple versus single IL-2 treatment of transplanted murine colon carcinoma. Cancer Immunol Immunother 53:445-452. (Pubitemid 38678534)
193. Henriksson R, Widmark A, Bergh A, Damber JE. 1992. Interleukin-2-induced growth inhibition of prostatic adenocarcinoma (Dunning R3327) in rats. Urol Res 20:189-191.
194. Yoshida S, Tanaka R, Takai N, Ono K. 1988. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res 48:5011-5016. (Pubitemid 18224469)